Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic and fibrotic pathways, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference on September 3, featuring a fireside chat at 1:35 p.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9. A webcast of the Cantor presentation will be available on Sagimet's website for 90 days after the event.
Sagimet Biosciences (Nasdaq: SGMT), azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per i percorsi metabolici e fibrotici, ha annunciato la sua partecipazione a due conferenze per investitori previste a settembre 2025.
L'azienda presenterà al Cantor Global Healthcare Conference il 3 settembre, con una fireside chat alle 13:35 ET, e al H.C. Wainwright 27th Annual Global Investment Conference il 9 settembre. Una trasmissione in webcast della presentazione al Cantor sarà disponibile sul sito di Sagimet per 90 giorni dopo l'evento.
Sagimet Biosciences (Nasdaq: SGMT), una compañía biofarmacéutica en fase clínica centrada en desarrollar terapias para vías metabólicas y fibróticas, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2025.
La compañía presentará en el Cantor Global Healthcare Conference el 3 de septiembre, con una charla junto al fuego a la 1:35 p.m. ET, y en el H.C. Wainwright 27th Annual Global Investment Conference el 9 de septiembre. La transmisión por webcast de la presentación en Cantor estará disponible en la web de Sagimet durante 90 días tras el evento.
Sagimet Biosciences (Nasdaq: SGMT)는 대사 및 섬유화 경로 치료제 개발에 주력하는 임상 단계의 바이오제약 회사로, 2025년 9월에 열리는 두 건의 투자자 컨퍼런스에 참가할 예정이라고 발표했습니다.
회사는 9월 3일 Cantor Global Healthcare Conference에서 오후 1시 35분(동부시간)에 파이어사이드 채팅을 진행하고, 9월 9일에는 H.C. Wainwright 27th Annual Global Investment Conference에서 발표할 예정입니다. Cantor 발표의 웹캐스트는 행사 종료 후 90일간 Sagimet 웹사이트에서 시청할 수 있습니다.
Sagimet Biosciences (Nasdaq: SGMT), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements pour les voies métaboliques et fibreuses, a annoncé sa participation à deux conférences destinées aux investisseurs en septembre 2025.
La société présentera lors du Cantor Global Healthcare Conference le 3 septembre, avec une discussion en fireside chat à 13h35 ET, et au H.C. Wainwright 27th Annual Global Investment Conference le 9 septembre. Une diffusion en webcast de la présentation Cantor sera disponible sur le site de Sagimet pendant 90 jours après l'événement.
Sagimet Biosciences (Nasdaq: SGMT), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Therapeutika für metabolische und fibrotische Signalwege konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am Cantor Global Healthcare Conference am 3. September präsentieren und dort um 13:35 Uhr ET an einem Fireside-Chat teilnehmen, sowie am H.C. Wainwright 27th Annual Global Investment Conference am 9. September. Ein Webcast der Cantor-Präsentation wird für 90 Tage nach der Veranstaltung auf der Sagimet-Website verfügbar sein.
- None.
- None.
SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
- Cantor Global Healthcare Conference in New York on September 3, 2025, with a fireside chat at 1:35 p.m. ET / 10:35 a.m. PT; and
- H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9, 2025.
A webcast of the Cantor fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Advisors
mfitzhugh@lifescicomms.com
FAQ
When is Sagimet Biosciences (SGMT) presenting at the Cantor Global Healthcare Conference?
Where can I watch Sagimet Biosciences' (SGMT) Cantor Conference presentation?
Which investor conferences is Sagimet Biosciences (SGMT) attending in September 2025?
What type of company is Sagimet Biosciences (SGMT)?
